These stories show how our momentum of discovery is changing the lives of cancer patients.
Identifying BCL-2 as a protein that cancer cells use to prevent self-destruction leads to the BCL-2 inhibitor venetoclax, a powerful agent against CLL and AML.
Identifying the EGFR mutation leads to the first broad application of precision medicine in lung cancer and paves the way for other active targeted lung cancer therapies.
PD-L1 AND CTLA-4 PATHWAYS
Combining treatments of PD-L1 and CTLA-4 pathways creates a “double assault” that is effective for melanoma, kidney and other cancers.
NOBEL PRIZE WINNING RESEARCH
Understanding how cancer hijacks the body’s oxygen-sensing system leads to new therapies for kidney cancer, heart disease and more.
CDK4/6 inhibitors can block the proteins that cause breast cancer cells to multiply faster, leading to higher survival rates for many advanced breast cancers.
Protein degradation can target cancer-causing proteins and selectively destroy them right inside the cell, making a difference in multiple myeloma and other blood cancers.
Dana-Farber shares patient stories which may include descriptions of actual medical results. Dana-Farber provides personalized care for each patient based on their unique needs; their experiences and results will vary.